Ankylosing Spondylitis

The FDA has granted final approval to Zydus Lifesciences to manufacture and market generic indomethacin 50 mg suppositories, according to a company press release.

AUSTIN, Texas — A former NBA mascot encouraged attendees of the 2023 Rheumatology Nurses Society annual conference to make the most of every moment they have with their patients, as their time and empathy can make all the difference.

Patients with psoriatic arthritis and axial involvement experienced greater improvement when treated with upadacitinib 15 mg compared with placebo and adalimumab, according to data published in Arthritis Research & Therapy.

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

PHILADELPHIA — Patients who started TNF inhibitors earlier in their ankylosing spondyloarthritis disease course, vs. no initiation, have a higher risk for cardiovascular events, according to data presented at ACR Convergence 2022.

Upadacitinib demonstrated significant improvements in patients with non-radiographic axial spondyloarthritis when compared with a placebo at 14 weeks, according to data published in The Lancet.

Although most patients with axial spondyolarthritis understand the importance of regular physical activity, few have the knowledge and skills necessary to perform cardiorespiratory training, according to data published in BMC Rheumatology.

After a third COVID-19 vaccine dose, patients with autoimmune rheumatic diseases often fail to mount an effective response useful in preventing omicron breakthrough infection, according to data published in Annals of the Rheumatic Diseases.

Although ankylosing spondylitis correlates with higher rates of Alzheimer’s disease, patients who receive TNF inhibitors are less likely to develop the neurologic disorder, according to data published in Pharmacological Research.

Upadacitinib is efficacious over 14 weeks in patients with ankylosing spondylitis who mounted poor responses to biologic disease-modifying antirheumatic drugs, according to data published in the Annals of the Rheumatic Diseases.